Trexquant Investment’s UroGen Pharma URGN Stock Holding History

Trexquant Investment’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-73,905	Closed	-$1.33M	–	2252
2026 Q1	$1.33M	Buy	+73,905	New	+$1.48M	0.01%	1135
2025 Q4	–	Sell	-116,436	Closed	-$2.32M	–	1949
2025 Q3	$2.32M	Buy	+116,436	New	+$2.09M	0.02%	856
2025 Q2	–	Sell	-15,454	Closed	-$171K	–	1900
2025 Q1	$171K	Sell	15,454 -157,097	-91%	-$1.67M	﹤0.01%	1482
2024 Q4	$1.84M	Sell	172,551 -99,119	-36%	-$1.19M	0.02%	891
2024 Q3	$3.45M	Buy	271,670 +190,961	+237%	+$2.83M	0.04%	616
2024 Q2	$1.35M	Buy	+80,709	New	+$1.15M	0.02%	894
2023 Q3	–	Sell	-14,763	Closed	-$153K	–	1845
2023 Q2	$153K	Buy	+14,763	New	+$163K	﹤0.01%	1349
2022 Q3	–	Sell	-30,407	Closed	-$249K	–	1855
2022 Q2	$249K	Buy	30,407 +12,211	+67%	+$83.9K	0.01%	1223
2022 Q1	$158K	Buy	+18,196	New	+$142K	0.01%	1239
2021 Q1	–	Sell	-15,812	Closed	-$285K	–	1485
2020 Q4	$285K	Buy	+15,812	New	+$331K	0.03%	712

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Trexquant Investment's URGN Position: Q2 2026 in Review

Trexquant Investment sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 73,905 shares — an estimated $1.33M sold.

Trexquant Investment first reported a position in URGN in Q4 2020 and held it in 10 quarters. The position peaked at $3.45M in Q3 2024. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Trexquant Investment reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Trexquant Investment sold 73,905 UroGen Pharma shares in Q2 2026, an estimated $1.33M.
Trexquant Investment first reported a position in UroGen Pharma in Q4 2020 and held it in 10 quarters.
Trexquant Investment's UroGen Pharma position peaked at $3.45M in Q3 2024.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.